Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback